Frequent questions on GLP-1 weight loss and Ozempic Face

'Ozempic Face' is the informal name for the hollow, gaunt or aged appearance that can follow rapid weight loss on GLP-1 medications such as Ozempic, Wegovy and Mounjaro. It is caused by loss of subcutaneous facial fat and, often, loss of muscle mass — not by the drugs themselves, but by the speed and composition of the weight loss they enable.

Most volume changes are not fully reversible because adult facial fat compartments do not fully repopulate after rapid loss. However, structured intervention — protein optimisation, resistance training, targeted skincare and, when appropriate, dermatological procedures — can meaningfully restore tone, firmness and youthful appearance.

Clinical and dermatological observations suggest that losing more than roughly 1% of body weight per week (about 0.5–1 kg for most adults) accelerates facial deflation and increases muscle loss. A slower titration and a deliberate plateau strategy generally protect both the face and lean mass.

Most adults on a GLP-1 should aim for 1.6 to 2.2 grams of protein per kilogram of lean body mass per day, divided across 3–4 meals of 25–40 g each. This range is designed to preserve muscle during a calorie deficit and is significantly higher than the standard 0.8 g/kg RDA.

Yes. Published data show that pairing higher protein intake with resistance training roughly halves the proportion of weight lost as muscle. Two or three sessions per week of compound strength work is typically enough to protect lean mass — and, indirectly, facial structure.

A 20-week study published in JAMA Dermatology found that a structured facial-exercise programme produced measurable improvement in upper- and lower-cheek fullness in middle-aged women. Facial exercises are not a substitute for protein and training, but they are a low-cost, evidence-based complement.

Fillers can restore volume in specific areas, but they do not address the underlying loss of muscle and skin quality. Most dermatologists recommend stabilising weight first, optimising nutrition and skincare, and only then considering fillers as a targeted finishing tool — not as a first response.

Retinoids, vitamin C, peptides, niacinamide and broad-spectrum sunscreen have the strongest evidence for supporting skin elasticity and collagen synthesis during periods of rapid weight loss. Hydration and barrier-supporting moisturisers also matter more than usual.

Current evidence suggests GLP-1 receptor agonists are well-tolerated for most patients when prescribed and monitored appropriately. Long-term data is still accumulating. Decisions about starting, continuing or stopping should always be made together with your prescribing physician.

Studies show that a significant share of patients regain a substantial portion of weight within 12 months of stopping GLP-1 therapy unless they have built durable habits around protein, training and sleep during treatment. The protocol matters as much as the medication.

Yes. GLP-1 drugs reduce appetite and often reduce drinking too. Mild dehydration worsens hunger signals, training quality, digestion and scale volatility. Most users benefit from drinking water before each meal and around training sessions.

The complete evidence-based protocol — eight pillars of facial preservation, 40+ cited studies, plus practical chapters — is available in the book 'Ozempic Face — Lose the Weight, Keep the Face' by Lucy Kant. A free excerpt with the Introduction and Chapter 1 is available on this site.